Milnacipran
- Generic Name
- Milnacipran
- Brand Names
- Savella
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N2O
- CAS Number
- 92623-85-3
- Unique Ingredient Identifier
- G56VK1HF36
- Background
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional ...
- Indication
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above .
...
- Associated Conditions
- Fibromyalgia
- Associated Therapies
- -
Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2010-07-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 2
- Registration Number
- NCT00793520
- Locations
- 🇺🇸
Forest Investigative Site, Ann Arbor, Michigan, United States
FMS European Long-Term Study
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 490
- Registration Number
- NCT00757731
- Locations
- 🇷🇴
Dr I CANTACUZINO CLINICAL HOSPITAL, Bucharest, Romania
🇨🇿Rheumatology Ambulance, Pardubice, Czech Republic
🇫🇮Kuopion Oma Laakari Oy, Kuopio, Finland
Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 153
- Registration Number
- NCT00757679
- Locations
- 🇨🇭
Clinical Pharmacology & Toxicology Multidisciplinary Pain Centre, Geneve, Switzerland
Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke?
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2008-10-17
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT00606203
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Chiayi, Taiwan
A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 1429
- Registration Number
- NCT00436033
- Locations
- 🇨🇿
Rheumatology Ambulance, Pardubice, Czech Republic
🇩🇰FREDERIKSBERG HOSPITAL - Clinic of Rheumatology, Frederiksberg, Denmark
🇮🇹Ospedale Luigi Sacco, Milano, Italy
Study Evaluating Effexor XR for Major Depression.
- Conditions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2007-05-24
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 590
- Registration Number
- NCT00225511
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.